Limits...
Clinical Features, Treatment, and Outcome of HIV-Associated Immune Thrombocytopenia in the HAART Era.

Ambler KL, Vickars LM, Leger CS, Foltz LM, Montaner JS, Harris M, Dias Lima V, Leitch HA - Adv Hematol (2012)

Bottom Line: The characteristics of HIV-associated ITP were documented prior to the HAART era, and the optimal treatment beyond HAART is unknown.This is to our knowledge the largest series of severe HIV-associated ITP reported in the HAART era.New approaches to the treatment of severe ITP in this population are needed.

View Article: PubMed Central - PubMed

Affiliation: Division of Hematology, University of British Columbia, 2775 Laurel Street, Vancouver, BC, Canada V5Z 1M9.

ABSTRACT
The characteristics of HIV-associated ITP were documented prior to the HAART era, and the optimal treatment beyond HAART is unknown. We performed a review of patients with HIV-associated ITP and at least one platelet count <20 × 10(9)/L since January 1996. Of 5290 patients in the BC Centre for Excellence in HIV/AIDS database, 31 (0.6%) had an ITP diagnosis and platelet count <20 × 10(9)/L. Initial ITP treatment included IVIG, n = 12; steroids, n = 10; anti-RhD, n = 8; HAART, n = 3. Sixteen patients achieved response and nine patients achieved complete response according to the International Working Group criteria. Median time to response was 14 days. Platelet response was not significantly associated with treatment received, but complete response was lower in patients with a history of injection drug use. Complications of ITP treatment occurred in two patients and there were four unrelated deaths. At a median followup of 48 months, 22 patients (71%) required secondary ITP treatment. This is to our knowledge the largest series of severe HIV-associated ITP reported in the HAART era. Although most patients achieved a safe platelet count with primary ITP treatment, nearly all required retreatment for ITP recurrence. New approaches to the treatment of severe ITP in this population are needed.

No MeSH data available.


Related in: MedlinePlus

Maximum platelet response.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3368161&req=5

fig2: Maximum platelet response.

Mentions: Overall, 25 patients achieved a CR or R according to the IWG criteria (see Figure 2). The median platelet response within 30 days was 58 (5–322) × 109/L and the median time to R was 14 (1–3192) days.


Clinical Features, Treatment, and Outcome of HIV-Associated Immune Thrombocytopenia in the HAART Era.

Ambler KL, Vickars LM, Leger CS, Foltz LM, Montaner JS, Harris M, Dias Lima V, Leitch HA - Adv Hematol (2012)

Maximum platelet response.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3368161&req=5

fig2: Maximum platelet response.
Mentions: Overall, 25 patients achieved a CR or R according to the IWG criteria (see Figure 2). The median platelet response within 30 days was 58 (5–322) × 109/L and the median time to R was 14 (1–3192) days.

Bottom Line: The characteristics of HIV-associated ITP were documented prior to the HAART era, and the optimal treatment beyond HAART is unknown.This is to our knowledge the largest series of severe HIV-associated ITP reported in the HAART era.New approaches to the treatment of severe ITP in this population are needed.

View Article: PubMed Central - PubMed

Affiliation: Division of Hematology, University of British Columbia, 2775 Laurel Street, Vancouver, BC, Canada V5Z 1M9.

ABSTRACT
The characteristics of HIV-associated ITP were documented prior to the HAART era, and the optimal treatment beyond HAART is unknown. We performed a review of patients with HIV-associated ITP and at least one platelet count <20 × 10(9)/L since January 1996. Of 5290 patients in the BC Centre for Excellence in HIV/AIDS database, 31 (0.6%) had an ITP diagnosis and platelet count <20 × 10(9)/L. Initial ITP treatment included IVIG, n = 12; steroids, n = 10; anti-RhD, n = 8; HAART, n = 3. Sixteen patients achieved response and nine patients achieved complete response according to the International Working Group criteria. Median time to response was 14 days. Platelet response was not significantly associated with treatment received, but complete response was lower in patients with a history of injection drug use. Complications of ITP treatment occurred in two patients and there were four unrelated deaths. At a median followup of 48 months, 22 patients (71%) required secondary ITP treatment. This is to our knowledge the largest series of severe HIV-associated ITP reported in the HAART era. Although most patients achieved a safe platelet count with primary ITP treatment, nearly all required retreatment for ITP recurrence. New approaches to the treatment of severe ITP in this population are needed.

No MeSH data available.


Related in: MedlinePlus